Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure
Executive Summary
Failure of small NASH cirrhosis study does not present much read-through to the larger class of NASH drugs in development. Galectin hopes its ongoing Phase IIb trial will validate its galectin-3 inhibitor in a more advanced disease state than most NASH candidates are pursuing.
You may also be interested in...
NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs
Although guidance appears to be free of surprises, US FDA once again made a push for sponsors to adopt seamless trial designs.
Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint
Company is moving its galectin-3 inhibitor into Phase III in non-alcoholic steatohepatitis patients with cirrhosis – a very advanced disease setting – and also to validate endpoints that don’t require liver biopsy.
Galectin Offers Subgroup Approach For Struggling NASH Candidate
Having failed to meet its primary endpoint in consecutive Phase II studies, Galectin hopes to move GR-MD-02 forward in NASH in patients with cirrhosis who have not developed esophageal varices.